Nissay Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Nissay Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,801	Closed	-$581K	–	769
2021 Q1	$581K	Sell	7,801 -59	-0.8%	-$5.44K	0.01%	674
2020 Q4	$1.34M	Buy	7,860 +289	+4%	+$42.8K	0.02%	516
2020 Q3	$1.06M	Buy	7,571 +211	+3%	+$32.1K	0.02%	519
2020 Q2	$1.18M	Buy	7,360 +684	+10%	+$93.1K	0.02%	476
2020 Q1	$653K	Buy	6,676 +254	+4%	+$29K	0.02%	530
2019 Q4	$829K	Buy	6,422 +914	+17%	+$92.3K	0.02%	572
2019 Q3	$415K	Buy	+5,508	New	+$650K	0.01%	678

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nissay Asset Management's SRPT Position: Q2 2021 in Review

Nissay Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2021, closing a stake of 7,801 shares — an estimated $581K sold.

Nissay Asset Management first reported a position in SRPT in Q3 2019 and held it in 7 quarters. The position peaked at $1.34M in Q4 2020. 330 funds tracked by Wall St. Rank hold SRPT as of Q2 2021.

Nissay Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2021 after selling out during the quarter.
Nissay Asset Management sold 7,801 Sarepta Therapeutics shares in Q2 2021, an estimated $581K.
Nissay Asset Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 7 quarters.
Nissay Asset Management's Sarepta Therapeutics position peaked at $1.34M in Q4 2020.
330 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2021.

Based on Nissay Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.